CREATV BIO STUDIES PRESENTED AT AACR ANNUAL MEETING SHOWING IMPORTANCE OF MONITORING PD-L1, MITOTIC CTCs and CAMLs IN BLOOD

Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"), a cancer diagnostic blood testing company, presented five posters in conjunction with several research collaborators at the 2026 AACR ...
News-Medical.Net

Polymer-based immunotherapies enhance tumor targeting and immune activation

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but ...
ascopubs.org

Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A ...

Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting. Outcome of chemo-immunotherapy for extensive-stage small-cell lung cancer according ...

PD-L1 X 4-1BB (CD137) Bispecific Antibodies Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Bispecific Antibodies by Drug Modality

The main market opportunities for PD-L1 x 4-1BB bispecific antibodies lie in their ability to target tumors precisely while minimizing liver toxicity, addressing a gap in cancer therapy. These ...
Targeted Oncology

Checkpoint Inhibitors in Lung Cancer: When One Drug Isn't Enough

Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
ascopubs.org

PD-1 inhibitors versus PD-L1 inhibitors in PD-L1–negative advanced non-small cell lung cancer: A meta-analysis of survival outcomes.

Predictive value of the triglyceride-glucose index for the efficacy of immunotherapy in patients with advanced NSCLC: A retrospective study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...